Nevertheless, the findings that eIF3a may suppress the synthesis of DNA repair proteins and contribute to the increased sensitivity of cancer cells to DNA-damaging treatments suggest that eIF3a may be developed as a biomarker for precision medicine prescription. The gene discussed is PROS1; the disease is cancer.